Role of Mitochondria in Non Severe Asthma

NCT00808730 | Completed

• 1 other identifier: CHUBX 2008/29
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

Asthma is a frequent disease characterized by bronchial hyperresponsiveness, inflammation and remodelling. Bronchial remodelling is an abnormal repair process that contributes to the development of poorly reversible airway narrowing. It can appear very early in the evolution of the disease and involves an increased mass of bronchial smooth muscle (BSM). The mechanism of such an increase has been related with an increase in smooth muscle cell proliferation. Recently, we have demonstrated that, BSM increased proliferation is induced by an enhanced mitochondrial biogenesis in severe asthma (T. Trian et al. J Exp Med 2007). The objective of this study is to investigate the role of smooth muscle cell mitochondria in non severe asthma

Conditions

Asthma

Keywords

Asthma, airway remodelling, smooth muscle, mitochondria

Outcome Measures

Primary Outcomes (1)

• BSM mitochondrial biogenesis assessed by the number of mitochondrial sections using electron microscopy, the porin content using western blot, and mitochondrial oxygen consumption evaluated by oxygraphy.

  One bronchial fiberoptic fibroscopy within 15 days after the enrolment

Secondary Outcomes (2)

• BSM remodelling assessed by optic microscopy and immunohistochemistry (using anti-alpha smooth muscle actin antibody).

  One bronchial fiberoptic fibroscopy within 15 days after the enrolment

• Transcription factors involved in mitochondrial biogenesis assessed by quantitative RT-PCR and western blot.

  One bronchial fiberoptic fibroscopy within 15 days after the enrolment

Study Arms (1)

1

EXPERIMENTAL

fiberoptic fibroscopy

Procedure: fiberoptic fibroscopy

Interventions

fiberoptic fibroscopy PROCEDURE

Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female aged more than 18 years
• Diagnosis of intermittent asthma, mild persistent asthma or moderate persistent according to ATS criteria
• Forced expiratory volume in one second \> 60% predicted
• Written informed consent

You may not qualify if:

• Smoker or former smoker (tobacco or cannabis)
• Adults protected by law
• Subjects not affiliated with social security
• Subject with any co-morbidity (except chronic rhinitis, chronic sinusitis nasal polyps or gastro-oesophageal reflux)
• Asthma exacerbation within 6 weeks before enrolment
• Infections of the upper airway within 3 months before enrolment
• Chronic viral infections (hepatitis, HIV)
• Pregnancy or breastfeeding
• Contraindications to bronchoscopy

Sponsors & Collaborators

• University Hospital, Bordeaux: lead

Study Sites (1)

University Hospital Bordeaux, Hôpital Haut-Lévêque

Pessac, 33604, France

Location

Related Publications (2)

• Trian T, Benard G, Begueret H, Rossignol R, Girodet PO, Ghosh D, Ousova O, Vernejoux JM, Marthan R, Tunon-de-Lara JM, Berger P. Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma. J Exp Med. 2007 Dec 24;204(13):3173-81. doi: 10.1084/jem.20070956. Epub 2007 Dec 3.

  PMID: 18056286 BACKGROUND

• Girodet PO, Allard B, Thumerel M, Begueret H, Dupin I, Ousova O, Lassalle R, Maurat E, Ozier A, Trian T, Marthan R, Berger P. Bronchial Smooth Muscle Remodeling in Nonsevere Asthma. Am J Respir Crit Care Med. 2016 Mar 15;193(6):627-33. doi: 10.1164/rccm.201507-1404OC.

  PMID: 26540234 DERIVED

MeSH Terms

Conditions

Asthma; Airway Remodeling

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Pierre-Olivier GIRODET, MCU-PH

  University Hospital Bordeaux / Département de Pharmacologie, CIC - Université Victor Segalen Bordeaux 2

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: December 15, 2008
• First Posted: December 16, 2008
• Study Start: February 1, 2009
• Primary Completion: November 1, 2009
• Study Completion: November 1, 2009
• Last Updated: February 17, 2010

Record last verified: 2010-02

Locations

FR (1)